InnoCare

InnoCare was founded in 2013 by Dr. Yi Gong Shi and Dr. Ji Song Cui, and is currently controlled by Dr. Ji Song Cui and Dr. Ren Bin Zhao, the wife of Dr. Yi Gong Shi. The company is committed to providing advanced innovative drugs for patients worldwide who are fighting cancer and immune system diseases. As an innovative drug developer, the company mainly provides checkpoint inhibitors, regulatory T cell inhibitors, and tumor-associated macrophage (TAM) modulators for patients with autoimmune diseases and cancers. These products are also used in the treatment of solid tumors, gastric cancer, chronic lymphocytic leukemia, rheumatoid arthritis, systemic lupus erythematosus, and other autoimmune diseases. According to the disclosure in InnoCare's prospectus, its product pipeline currently includes five main research and development products targeting five different targets. Three of these products have entered the clinical stage, while the other two are still in the preclinical stage.Its leading product, Orelabrutinib (ICP-022), is a potential Best in Class novel BTK inhibitor for the treatment of various B-cell malignancies and autoimmune diseases. So far, the development of Orelabrutinib has been proceeding very smoothly, and the new drug applications (NDA) for its two major indications have been accepted by China’s National Medical Products Administration (CDE). Orelabrutinib has demonstrated significant efficacy in clinical trials and shown better safety than similar products. InnoCare is also currently preparing for sales-related activities.ICP-192 and ICP-105 are two other drug pipelines of InnoCare that are currently in the clinical stage, targeting pan-FGFR and FGFR4, respectively. Within China, ICP-192 is already the fastest progressing pan-FGFR inhibitor besides Erdafitinib. Regarding FGFR4 inhibitors, only InnoCare's ICP-105 and CStone Pharmaceuticals' CS3008 have entered clinical trials in China. This means both drugs are currently among the top tier in the country.In terms of preclinical drug reserves, InnoCare has developed six preclinical candidate drugs. Among them, ICP-723 and ICP-330 have almost completed preclinical research and are ready to enter the clinical stage.